SCHEMBL374844

SCHEMBL374844

Fc1ccc(CNC2CCSCC2)cc1Br

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.51
POLB P06746 1/20 0.40
HRH3 Q9Y5N1 1/20 0.38
HDAC1 Q13547 1/20 0.38
MEN1 O00255 1/20 0.36
RAB9A P51151 1/20 0.36
KMT2A Q03164 1/20 0.36
KDM1A O60341 1/20 0.36
IDO1 P14902 1/20 0.36
BCHE P06276 1/20 0.35
ACHE P22303 1/20 0.35
BACE1 P56817 1/20 0.35
ALDH1A1 P00352 1/20 0.35
CARM1 Q86X55 2/20 0.34
PRMT6 Q96LA8 2/20 0.34
PRMT8 Q9NR22 1/20 0.34
CCR3 P51677 1/20 0.34
MITF O75030 1/20 0.34
SSTR3 P32745 1/20 0.34
DYRK1A Q13627 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL999995 0.86 POLB (0.54) KDM4EPOLBHRH3HDAC1IDO1
SCHEMBL15104570 0.86 POLB (0.50) KDM4EPOLBHRH3HDAC1MEN1
SCHEMBL1000678 0.85 HRH3 (0.56) KDM4EPOLBHRH3HDAC1IDO1
SCHEMBL374926 0.82 PARP1 (0.43) KDM4EPOLBHRH3MEN1RAB9A
SCHEMBL23124848 0.76 KCNH2 (0.45) POLBHRH3HDAC1MEN1RAB9A
SCHEMBL375294 0.74 KDM1A (0.37) KDM4EPOLBKDM1AALDH1A1CARM1
SCHEMBL1566841 0.74 POLB (0.46) POLBHRH3ALDH1A1SSTR3
SCHEMBL375612 0.72 HTT (0.62) KDM4EPOLBMEN1RAB9AKMT2A
SCHEMBL375127 0.70 CARM1 (0.59) POLBMEN1KMT2AIDO1BCHE
SCHEMBL15525035 0.69 MEN1 (0.35) POLBHRH3MEN1RAB9AKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8623898-B2 Glycine transporter inhibiting substances TAISHO PHARMACEUTICAL CO., LTD. (JP) 2014-01-07 US disclosed
US-8623898-B2 Glycine transporter inhibiting substances TAISHO PHARMACEUTICAL CO., LTD. (JP) 2014-01-07 US disclosed
US-8623898-B2 Glycine transporter inhibiting substances TAISHO PHARMACEUTICAL CO., LTD. (JP) 2014-01-07 US disclosed
EP-2409976-A1 GLYCINE TRANSPORTER INHIBITOR Taisho Pharmaceutical Co., Ltd. (JP) 2012-01-25 EP disclosed
US-20120010414-A1 GLYCINE TRANSPORTER INHIBITING SUBSTANCES TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-01-12 US disclosed
US-20120010414-A1 GLYCINE TRANSPORTER INHIBITING SUBSTANCES TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-01-12 US disclosed
US-20120010414-A1 GLYCINE TRANSPORTER INHIBITING SUBSTANCES TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-01-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120010414-A1 GLYCINE TRANSPORTER INHIBITING SUBSTANCES SLC18A2, SLC1A2, SLC6A1 KDM4E 4384/4885POLB 3019/4885HRH3 464/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.